Immunai and Teva launch multi-tear AI collaboration for smarter drug development
The partnership will utilize Immunai’s cutting-edge immune system mapping tools to enhance precision in immunology and oncology trials.
Artificial intelligence (AI) biotech company Immunai, which specializes in mapping the human immune system, has announced a multi-year collaboration with Teva Pharmaceuticals. Under this agreement, Immunai will collaborate with Teva in Immunology and Immuno-oncology programs.
This collaboration will leverage Immunai’s proprietary immune cell atlas, AMICA, and its AI model, the Immunodynamics Engine (IDE), to enhance clinical decision-making in Teva's Immunology trials. Key focus areas will include drug mechanism of action, dose selection, and biomarker analyses.
“This collaboration reflects our ongoing efforts in enhancing drug development within immunology and immuno-oncology. Bringing a drug to market is inherently challenging, time-consuming, and costly,” said Noam Solomon, Ph.D., CEO of Immunai. “Through our partnership with Teva, we are eager to utilize our AI-based engine, the Immunodynamics Engine (IDE), to streamline this process and facilitate the delivery of new therapies to patients.”
Related articles:
“At Teva, we are always looking to unlock what’s next in science and working with Immunai to harness the power of their cutting-edge tools and AI solutions will help us to step up innovation to drive forward our research and development strategy,” said Eran Harary, MD, Senior Vice President of Global Early Clinical Development at Teva. “This collaboration will provide important insights into patient responses and treatment mechanisms in immunology and immuno-oncology, allowing us to optimize our clinical trials and improve outcomes for patients.”
Less than two months ago, Immunai announced a multi-year collaboration with AstraZeneca. Under the terms of the agreement, Immunai is set to receive $18 million for the initial phase of the collaboration.
The collaboration will focus on clinical decision-making, including dose selection, elucidating mechanisms of action, patient responder vs. non-responder analysis, and biomarker identification, by leveraging Immunai’s AI model of the immune system, the IDE.
Immunai, which employs 170 people, 85 of whom are PhDs or MDs, raised a $215 million Series B at a valuation of just over $1 billion in 2021. It has raised a total of $295 million to date.
